PTAB: Reexamination Does Not Reset the One-Year Deadline For Filing a Petition for Inter Partes Review

Jun 5, 2019

Reading Time : 2 min

On October 2, 2014, Patent Owner filed a lawsuit in district court accusing Petitioner of infringing several claims of U.S. Patent No. 7,039,033 (the “’033 Patent”). In response, Petitioner filed an IPR (the “original IPR”) challenging the validity of the claims that Patent Owner had asserted against it in district court. The Board instituted the original IPR and ultimately held that all of the challenged claims were unpatentable. The Federal Circuit upheld the Board’s determination and thereafter the Board issued a certification cancelling all claims of the ’033 Patent challenged in the original IPR. Notably, while the Federal Circuit appeal was pending, Patent Owner sought ex parte reexamination of the ’033 Patent. The Patent Office granted the reexamination request and issued a reexamination certificate adding 68 new claims to the ’033 Patent. On November 18, 2018, within one year of the reexamination certificate being granted, Petitioner filed six IPRs (the “present IPRs”) challenging the validity of the new claims that were added to the ’033 Patent during reexamination.

The Board, however, declined institution of these IPRs because it found they were filed more than one year after the Petitioner was served with the district court complaint on October 2, 2014. These petitions were, therefore, time-barred under § 315(b). In reaching its decision, the Board rejected Petitioner’s argument that § 315(b)’s one-year time bar did not apply because Patent Owner’s ex parte reexamination certificate adding new claims created a new, materially different patent. The Board found that the Federal Circuit in Click-to-Call Technologies, LP v. Ingenio Inc. considered and rejected Petitioner’s argument, explaining that “reexamination does not result in the issuance of a new patent for purposes of § 315(b), regardless of claim scope.” Interestingly, the Board acknowledged that while its decision potentially forecloses the use of IPR for challenging reexamined claims, “Congress could have included in . . . [§] 315(b) language regarding the effect of reexamination on the deadline to file an IPR[,]” but chose not to do so.

The Board also denied Petitioner’s attempt to circumvent the § 315(b) time bar by joining the present IPRs to the original IPR. The Board first noted that the present IPRs were filed more than 34 months after the original IPR was instituted. Accordingly, Petitioner’s motion requesting joinder was filed several years after the one-month (post-institution) deadline set by the joinder rule and was therefore untimely. The Board further noted that even if the rules provide for joinder within one month of the issuance of a reexamination certificate, which they do not expressly do, Petitioner’s request was still several months late. Notwithstanding the joinder deadline, the Board also found that the original IPR was no longer pending before the Board and, therefore, it “cannot serve as a base proceeding to which [the present IPRs] may be joined.” Thus, the Board held that joinder was inappropriate for the independent reason that there was nothing for the present IPRs to join.

Practice Tip: Based on the Board’s current practice, a patent owner whose claims are found to be unpatentable in an IPR proceeding should consider—during the pendency of the proceeding, including an appeal of the Board’s determination—whether it could get new claims through ex parte reexamination. Any new claims that issue through reexamination may be immune from an IPR if the patent owner previously asserted the patent against the petitioner. Such consideration should also take into account any potential ramifications of intervening rights.

Apple Inc., v. IXI IP, LLC, IPR2019-00124, -00125, -00139, -00140, -00141, -00181 (PTAB June 3, 2019) (Tierney)

Share This Insight

Previous Entries

IP Newsflash

July 25, 2025

Earlier this year, the Federal Circuit’s decision in Qualcomm Inc. v. Apple Inc. (Qualcomm II) raised questions about the extent to which petitioners can rely on applicant admitted prior art (“AAPA”) in inter partes review proceedings.  The Federal Circuit’s recent decision in Shockwave Medical, Inc. v. Cardiovascular Sys., Inc. largely cabins the Qualcomm II decision to its particular facts and makes clear that AAPA can be used as evidence of background knowledge as part of an obviousness argument.

...

Read More

IP Newsflash

July 11, 2025

The Federal Circuit recently reversed a PTAB determination on remand that a patent was obvious over applicant admitted prior art (“AAPA”) in combination with prior art patents, holding that expressly designating AAPA as a “basis” for a ground is improper under 35 U.S.C. § 311(b). In doing so, the Court rejected the PTAB’s “blanket rule” that “AAPA used in combination with prior art patents or printed publications under § 311(b) is ipso facto not the basis or part of the basis of a ground.” Ultimately, while the case clarifies that expressly listing AAPA in an IPR ground is improper, the precise line between proper and improper uses of AAPA in other instances remains unclear.

...

Read More

IP Newsflash

July 1, 2025

In an appeal from an inter partes review, the Federal Circuit recently clarified that the enablement inquiry applied to prior art references in the context of an anticipation defense differs from the enablement inquiry applied when evaluating the claims of a patent.

...

Read More

IP Newsflash

June 26, 2025

The Northern District of Ohio denied a motion to compel the plaintiff to produce test results referenced in its initial disclosures and complaint. The court found that because the “test results are not facts but rather are opinions,” the information was protected as work product. Furthermore, because that testing would not be used as evidence in the litigation, the defendant was not prejudiced.

...

Read More

IP Newsflash

June 6, 2025

In a precedential opinion, the Federal Circuit definitively held that the Patent Trial and Appeal Board has jurisdiction over IPRs that concern expired patents.

...

Read More

IP Newsflash

June 6, 2025

In a patent infringement litigation in the U.S. District Court for the Eastern District of Texas, Judge Rodney Gilstrap denied a joint motion to stay the litigation pending resolution of inter partes review when it was uncertain that all defendants would be bound by the statutory estoppel provision of 35 U.S.C. § 315(e).

...

Read More

IP Newsflash

May 30, 2025

A district court recently dismissed a patent infringement complaint for improper venue under 28 U.S.C. § 1400(b), finding that the storage and distribution of products from an Amazon warehouse was not sufficient to establish that warehouse as a regular and established place of business in the district.

...

Read More

IP Newsflash

May 27, 2025

The Federal Circuit affirmed a District of Delaware finding of non-infringement in an ANDA litigation due to the patentee’s clear and unmistakable disavowal of claim scope during prosecution. Specifically, the court held that statements made during prosecution of a parent application before the asserted claims were allowed amounted to a prosecution disclaimer that extended to subsequent patents in the family. In reaching this conclusion, the court rejected an attempt by the patentee to resurrect the claim scope through a unilateral, self-serving statement made in later applications in the family.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.